U.S. markets close in 2 hours 2 minutes
  • S&P 500

    4,357.35
    -0.38 (-0.01%)
     
  • Dow 30

    33,979.22
    +8.75 (+0.03%)
     
  • Nasdaq

    14,743.99
    +30.09 (+0.20%)
     
  • Russell 2000

    2,187.74
    +5.54 (+0.25%)
     
  • Crude Oil

    70.43
    +0.14 (+0.20%)
     
  • Gold

    1,777.00
    +13.20 (+0.75%)
     
  • Silver

    22.53
    +0.37 (+1.68%)
     
  • EUR/USD

    1.1725
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.3210
    +0.0120 (+0.92%)
     
  • GBP/USD

    1.3655
    -0.0004 (-0.03%)
     
  • USD/JPY

    109.2530
    -0.1670 (-0.15%)
     
  • BTC-USD

    41,619.30
    -2,462.96 (-5.59%)
     
  • CMC Crypto 200

    1,039.27
    -24.57 (-2.31%)
     
  • FTSE 100

    6,980.98
    +77.07 (+1.12%)
     
  • Nikkei 225

    29,839.71
    -660.34 (-2.17%)
     

BD's (BDX) Digital Marketplace Set to Improve User Experience

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Becton, Dickinson and Company BDX, popularly known as BD, recently announced the commercial release of a new bdbiosciences.com web and eCommerce site. The digital marketplace has been designed with the aim of providing an improved online purchasing experience for users and their procurement teams.

For investors’ note, the new BD Biosciences website offers a full range of BD’s research, clinical and single-cell multiomic products. This, in turn, makes the online destination a comprehensive marketplace for flow cytometry users.

The newly launched website is available for users in the United States, Canada, Europe, Australia and New Zealand, and is set to be introduced in additional countries later this summer.

The latest release is expected to significantly strengthen BD’s position in the global Biosciences space. The Biosciences business is a part of the broader BD Life Sciences arm of the company.

Significance of the Release

Per management, the reimagined digital marketplace is aimed at empowering its customers with tools and relevant scientific content to make the process of online product search and purchase quicker, easier and more suitable throughout the complete flow cytometry continuum.

The entirely refurbished online purchasing experience brings intuitive navigation, a fully integrated shopping experience and a user interface theme that is expected to address flow cytometry users' buying needs. Tailored dashboards and quick checkout with minimal clicks, all with 24/7 order tracking and support tools are available for reagent purchases.

The eCommerce capability aids in seamless integration with procurement buying systems, thereby enabling customers to view institutional pricing and get internal approvals before placing orders.

Industry Prospects

Per a report by MarketsandMarkets, the global flow cytometry market is projected to grow from an estimated $4.0 billion in 2019 to $6.4 billion by 2025 at a CAGR of 8.3%. Factors like technological advancements in flow cytometers and the growing adoption of its techniques in research activities and clinical trials are likely to drive the market.

Given the market potential, the commercial release of the overhauled digital marketplace is expected to significantly strengthen BD’s business worldwide.

Notable Developments

Of late, BD has witnessed a few notable developments across its businesses.

The company, in June, received the FDA’s 510(k) clearance for its PeritX Peritoneal Catheter System. The system is to be used for the drainage of symptomatic, recurrent non-malignant ascites.

The same month, BD announced that it has been authorized as a Common Vulnerability and Exposures (“CVE”) Numbering Authority via the CVE Program. BD is the first medical technology company with such an authorization.

In May, the company announced the U.S. launch of a Urine Culture Application for use with the BD Kiestra lab automation incubation and imaging system.

Price Performance

Shares of BD have lost 2.9% in the past year compared with the industry’s 28.8% growth and the S&P 500's 40% rise.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Zacks Rank & Key Picks

Currently, BD carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Veeva Systems Inc. VEEV, AMN Healthcare Services Inc AMN and National Vision Holdings, Inc. EYE.

Veeva Systems’ long-term earnings growth rate is estimated at 15.8%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

AMN Healthcare’s long-term earnings growth rate is estimated at 6.5%. It currently flaunts a Zacks Rank #1.

National Vision’s long-term earnings growth rate is estimated at 23%. It currently sports a Zacks Rank #1.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Becton, Dickinson and Company (BDX) : Free Stock Analysis Report

AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report

Veeva Systems Inc. (VEEV) : Free Stock Analysis Report

National Vision Holdings, Inc. (EYE) : Free Stock Analysis Report

To read this article on Zacks.com click here.